Type 2 diabetes lowers weight loss by about one-third at the same dose: a diabetes trial produced about 10% loss at 2.4 mg versus 15% in non-diabetic obesity
(PubMed) Tort F, Ferrer-Cortes X, Thio M, et al
3.36 ml/min/m 2 per year), it led to more frequent discontinuation mainly due to gastrointestinal side effects [28]
Hormone-sensitive conditions Any patient with a history of hormone-sensitive breast cancer, endometriosis, or uterine fibroids should discuss resveratrol's estrogenic activity with their oncologist or gynecologist before starting it, regardless of their cardiovascular medications
However, if you have recurrent kidney stones alongside other metabolic risk factors such as obesity, diabetes, or abnormal liver function tests, your GP may assess your overall metabolic health and arrange appropriate investigations